Pfizer's SERM lasofoxifene headed for US panel review
This article was originally published in Scrip
The US FDA's reproductive health drugs advisory panel will meet on September 8th to consider Pfizer's selective oestrogen receptor modulator (SERM) Fablyn (lasofoxifene, formerly Oporia) for the treatment of osteoporosis. This is Pfizer's third attempt to get the troubled SERM, developed with Ligand Pharmaceuticals, approved in the US. The company originally filed lasofoxifene for osteoporosis prevention in August 2004, but the FDA issued a non-approvable letter. Pfizer's second proposed indication, vaginal atrophy, was also rejected. The NDA submitted last December for treatment in postmenopausal women at increased fracture risk contains three-year interim data from the Phase III, 8,556 patient PEARL study. Lilly's Evista (raloxifene) is the only SERM approved for osteoporosis. Wyeth has had trouble getting its SERM bazedoxifene licensed in the US, having received two approvable letters for a prevention indication and one for treatment.
You may also be interested in...
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.
IPEC-Americas requests an improved communications channel with the FDA and formal inclusion in talks to reauthorize the generic drug user fee program; agency says industry negotiators generally represent product manufacturers and API suppliers that are subject to user fees.
Generic drugs program has approved almost 300 manufacturing changes to help shore up the supply chain, with some prior approval supplements being downgraded to ‘changes being effected’ supplements, FDA officials said at GDUFA III kick-off meeting.